Celldex Therapeutics Inc (CLDX) Stock Analysis

Celldex Therapeutics Inc (CLDX) is a publicly traded company in the HEALTHCARE sector. It trades at $28.90, carries a market capitalization of $2.37B. This page summarizes the public market data, fundamentals, and frequently asked questions for CLDX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $28.90
• Market Cap: $2.37B
• EPS: $-4.27
• 52-Week High: $35.79
• 52-Week Low: $19.25

Market Sentiment

Celldex Therapeutics Inc currently has a Neutral sentiment score of 0.03.

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc. (CLDX) is a forward-thinking biopharmaceutical company headquartered in Hampton, New Jersey, dedicated to developing innovative therapeutic monoclonal and bispecific antibodies that target significant unmet medical needs in oncology and neurology. With a strong focus on proprietary technologies that enhance both the efficacy and safety profiles of its therapies, Celldex boasts a promising pipeline of clinical programs that underscore its leadership position in targe...

GNG Research Analysis

GNG Research scores Celldex Therapeutics Inc (CLDX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CLDX.

Frequently Asked Questions

Does CLDX pay dividends?

Celldex Therapeutics Inc (CLDX) does not currently pay a regular dividend.

What is CLDX's market cap?

Celldex Therapeutics Inc (CLDX) has a market capitalization of $2.37B with a current stock price of $28.90.